Actinium Pharmaceuticals
ATNM
44 hedge funds and large institutions have $5.78M invested in Actinium Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 5 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
36% more capital invested
Capital invested by funds: $4.24M → $5.78M (+$1.54M)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
2% more funds holding
Funds holding: 43 → 44 (+1)
0.23% more ownership
Funds ownership: 0.25% → 0.48% (+0.23%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.79M |
| 2 |
SCM
Sio Capital Management
New York
|
+$1.54M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$831K |
| 4 |
FI
Fosun International
Hong Kong,
China
|
+$181K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$52.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$513K |
| 2 |
DAM
DLD Asset Management
New York
|
-$68K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$28K |
| 4 |
Bank of New York Mellon
New York
|
-$23K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$20K |
ATNM Hedge Fund Activity: Q2 2019 in Review
44 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2019, worth a combined $5.78M — up 36% from $4.24M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ATNM positions and 5 closed out — a net gain of 1 holder — while 10 added to existing stakes and 6 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $2.79M. The largest seller was Vanguard Group, cutting an estimated $513K.
- 44 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2019, up from 43 in Q1 2019.
- Funds reported $5.78M of Actinium Pharmaceuticals stock for Q2 2019, up 36% quarter-over-quarter.
- 6 funds opened new Actinium Pharmaceuticals positions in Q2 2019 and 5 closed out, a net change of +1 holder.
- The largest Actinium Pharmaceuticals buyer in Q2 2019 was Sabby Management, an estimated $2.79M added.
- The largest Actinium Pharmaceuticals seller in Q2 2019 was Vanguard Group, an estimated $513K sold.
Based on aggregated 13F filings for Q2 2019.